Drug Profile
Research programme: cancer therapeutics - Arisaph Pharmaceuticals
Alternative Names: ARI-3996; ARI-6000; Immune stimulation/vaccines - Arisaph; Tumour activated pro-drugs - Arisaph; Tumour activated pro-soft drugs - Arisaph; Ultra-smart pro-drugs - Arisaph; Ultra-smart pro-soft drugs - ArisaphLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Arisaph Pharmaceuticals
- Developer Arisaph Pharmaceuticals; Fox Chase Cancer Center
- Class Small molecules; Vaccines
- Mechanism of Action Fibroblast activation protein antagonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 29 Sep 2014 Arisaph Pharmaceuticals receives supplemental phase I and phase II STTR grant from the US National Cancer Institute for development of drug candidates using different technologies in Cancer
- 31 Jul 2013 Arisaph Pharmaceuticals receives STTR grant from the US National Cancer Institute for development of small molecule immune modulators in Cancer